While serum prostate specific antigen (PSA) testing improved early detection of prostate tumors, implementation of this tool also created a large patient population in which identified cancer lesions were actually indolent. For patients who choose to undergo prostatectomy, cancer aggressiveness can only be determined by post-procedure pathology analysis of cancerous tissue. Additionally, cancer recurrence predictions are often unreliable. As an alternative method to aid decisions regarding treatment, we sought to develop MRS tools which can predict cancer aggressiveness based on the novel use of histologically benign (Hb) tissue.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords